Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial -

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial
Information type: Randomised controlled trials
Source: The Lancet HIV
Specialities: Infection and infectious diseases | Sexual health
Summary
RCT (n= 769) reported non-inferiority of the doravirine regimen in achieving plasma HIV-1 RNA of less than 50 copies per mL (84% vs 80% with darunavir; difference 3.9%, 95% CI −1.6 to 9.4).
UKMi comment
An editorial discusses the implications of these findings.
Related links: Editorial